Evidence map›Paper›PMID 41041288›Full record

ReviewRSC advances2025

Disulfiram as an anti-inflammatory agent: mechanisms, nano-delivery strategies, and applications in non-oncologic diseases.

Qiwen Jiang, Mengni Jiang, Yanwei Lv, Xinyuan Zhang, Shige Wang, Jiulong Zhao

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Qiwen JiangDepartment of Gastroenterology, Shanghai Institute of Pancreatic Diseases, Changhai Hospital, National Key Laboratory of Immunity and Inflammation, Naval Medical University Shanghai China jlzhao9@163.com.ORCID https://orcid.org/0009-0009-2394-4622
Mengni JiangDepartment of Gastroenterology, Shanghai Institute of Pancreatic Diseases, Changhai Hospital, National Key Laboratory of Immunity and Inflammation, Naval Medical University Shanghai China jlzhao9@163.com.
Yanwei LvDepartment of Gastroenterology, Shanghai Institute of Pancreatic Diseases, Changhai Hospital, National Key Laboratory of Immunity and Inflammation, Naval Medical University Shanghai China jlzhao9@163.com.
Xinyuan ZhangSchool of Materials and Chemistry, University of Shanghai for Science and Technology No. 516 Jungong Road Shanghai 200093 China sgwang@usst.edu.cn.
Shige WangSchool of Materials and Chemistry, University of Shanghai for Science and Technology No. 516 Jungong Road Shanghai 200093 China sgwang@usst.edu.cn.ORCID https://orcid.org/0000-0002-7639-6035
Jiulong ZhaoDepartment of Gastroenterology, Shanghai Institute of Pancreatic Diseases, Changhai Hospital, National Key Laboratory of Immunity and Inflammation, Naval Medical University Shanghai China jlzhao9@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Disulfiram (DSF), an FDA-approved drug for alcoholism, has recently emerged as a potent anti-inflammatory agent. It achieves this by targeting gasdermin D (GSDMD)-mediated pyroptosis, a key driver of inflammatory responses. This review explores the multifaceted anti-inflammatory mechanisms of DSF, including its inhibition of GSDMD pore formation, modulation of the STING pathway, suppression of RIPK1-dependent necroptosis, and disruption of FROUNT-mediated macrophage migration. Despite its promising

Identifiers

PMID41041288
PMCPMC12486247

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.